following a full submission:
retigabine (Trobalt®) is accepted for restricted use within NHS Scotland.
Indication under review: Adjunctive treatment of partial onset seizures with or without secondary generalisation in adults aged 18 years and above with epilepsy.
SMC restriction: patients with refractory epilepsy. Treatment should be initiated only by physicians who have appropriate experience in the treatment of epilepsy.
In two placebo-controlled studies in patients with refractory epilepsy retigabine was superior to placebo in terms of the proportion of patients experiencing 50% reduction in partial seizure frequency per 28 days. An indirect comparison indicates that retigabine has similar efficacy to two other antiepileptic drugs used as adjunctive therapy.
Download detailed advice144KB (PDF)
Medicine details
- Medicine name:
- retigabine (Trobalt)
- SMC ID:
- 712/11
- Indication:
- Adjunctive treatment of partial onset seizures without secondary generalisation in adults aged 18 years and above with epilepsy
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 11 July 2011